Yazar "Harputluoğlu, Hakan" için WoS İndeksli Yayınlar Koleksiyonu listeleme
-
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study
Ölmez, Ömer Fatih; Bilici, Ahmet; Er, Özlem; Bişgin, Atıl; Sevinç, Alper; Akman, Tülay; Uslu, Rüçhan; Molinas Mandel, Nil; Yalçın, Şuayib; Teomete, Mehmet; Görümlü, Gürbüz; Demir, Atakan; Namal, Esat; Alıcı, Süleyman; Selçukbiricik, Fatih; Bavbek, Sevil; Paksoy, Fatma; Başaran, Gül; Özer, Leyla; Şener, Nur; Harputluoğlu, Hakan; Kaya, Ali Osman; Yazar, Aziz; Afşar, Çiğdem Usul; Göker, Erdem; Şen, Fatma; Gököz Doğu, Gamze; Şeker, Mesut; Özkan, Metin; Türken, Orhan; Özveren, Ahmet; Orhan, Bülent; Yumuk, Fulden; Üskent, Necdet; Saip, Pınar; Şanlı, Ulus Ali; Dişel, Umut; Berk, Veli; Alakavuklar, Mehmet (2024)Objective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced ... -
The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey Molecular Profiling in Advanced Cancers Trial (TUMPACT)
Ölmez, Ömer Fatih; Bilici, Ahmet; Er, Özgür; Sevinç, Ali İbrahim; Akman, Tülay; Uslu, Rüçhan; Mandel, Nil Molinas; Yalçın, Şule; Teomete, Mehmet; Görümlü, Gürbüz; Demir, Ahmet Muzafer; Namal, Esat; Alıcı, Süleyman; Selçukbiricik, Fatih; Bavbek, Sevil; Paksoy, Fatma; Başaran, Gül; Özer, Leyla; Şener, Nazlı; Harputluoğlu, Hakan (Elsevier, 2020)Background: Molecular genetic profiling (MGP) which has started to take an important part in cancer diagnosis and treatment in recent years, has entered the routineclinical practice much faster than expected. We aimed to ... -
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
Esin, Ece; Çakmak Öksüzoğlu, Ömür Berna; Bilici, Ahmet; Çiçin, İrfan; Aksoy, Sercan; Alacacıoğlu, Ahmet; Kaplan, Mehmet Ali; Çabuk, Devrim; Sümbül, Ahmet Taner; Paydaş, Semra; Sakin, Ayşegül; Korkmaz, Tuba; Özdemir Yıldırım, Nuriye; Artaç, Mehmet; Harputluoğlu, Hakan; Yumuk, Perran Fulden; Atalay Başaran, Gül; Oyan Uluç, Başak; Demirci, Umut (Oxford University Press, 2018)... -
Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study)
Bilici, Ahmet; Ölmez, Ömer Fatih; Sezer, Ahmet; Öksüzoğlu, Berna; Kaplan, Muhammet Ali; Karadurmuş, Nuri; Çubukçu, Erdem; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Erdem, Dilek; Başaran, Gül; Çakar, Burcu; Şeker, Mesut; Arslan, Çağatay; Sezgin Göksu, Sema; Çiçin, İrfan; Gümüş, Mahmut; Selçukbiricik, Fatih; Harputluoğlu, Hakan; Helvacı, Kaan (Lippincott Williams and Wilkins, 2022)... -
Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
Artaç, Mehmet; Çubukçu, Erdem; Bozkurt, Oktay; Bilici, Ahmet; Çelik, S.; Özçelik, M.; Öven, B.; Şimşek, E.; Geredeli, C.; Karaca, M.; Cil, T.; Harputluoğlu, Hakan; Şendur, Mehmet Ali Nahit; Türk, H. Mehmet; Kefeli, Umut; Alacacıoğlu, Ahmet; Tural, D.; Sakin, A.; Karadurmuş, Nuri; Çevik, Duygu; Dane, Faysal; Gümüş, Mahmut (Elsevier, 2022)Background: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim ... -
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
Yıldırım, Mahmut Emre; Karaca, Mustafa; Artaç, Mehmet; Çiçin, İrfan; Geredeli, Çağlayan; Alacacıoğlu, Ahmet; Tanrıkulu Şimşek, Eda; Bilici, Ahmet; Harputluoğlu, Hakan; Özçelik, Melike; Bozkurt, Oktay; Yüksel, Sinemiş; Tural, Deniz; Sakin, Abdullah; Çil, Timuçin; Öven, Bala Başak; Dane, Faysal; Çevik, Duygu; Gümüş, Mahmut; Işıkdogan, Abdurrahman (Lippincott Williams and Wilkins, 2022)... -
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
Bilici, Ahmet; Öztürk, Türkan; Türkmen, Esma; Odabaş, Hatice; Cihan, Şener; Selçukbiricik, Fatih; Erdoğan, Bülent; Urakçı, Zuhat; Kandemir, Nurten; Bayoğu, İbrahim Vedat; Demirci, Umut; Ocak Duran, Ayşe; Şendur, Mehmet Ali; Yavuzer, Dilek; Harputluoğlu, Hakan; Kavgacı, Halil; Gümüş, Mahmut (Springer, 2015)Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...